SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Siber George

(Last)

(First)

(Middle)

2000 BROADWAY

PENTHOUSE 2B

(Street)

NEW YORK

10023

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/04/2014

3. Issuer Name and Ticker or Trading Symbol
GENOCEA BIOSCIENCES, INC. [ GNCA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,017	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to purchase Common Stock	⁽¹⁾	06/12/2017	Common Stock	10,084	$1.67	D
Option to purchase Common Stock	⁽¹⁾	06/18/2018	Common Stock	1,680	$2.38	D
Option to purchase Common Stock	⁽²⁾	06/30/2019	Common Stock	30,511	$2.38	D
Option to purchase Common Stock	⁽³⁾	12/17/2010	Common Stock	11,057	$2.86	D
Option to purchase Common Stock	⁽⁴⁾	07/26/2022	Common Stock	11,057	$1.79	D
Option to purchase Common Stock	⁽²⁾	07/26/2022	Common Stock	8,403	$1.79	D
Option to purchase Common Stock	⁽⁴⁾	07/26/2022	Common Stock	8,403	$1.79	D
Option to purchase Common Stock	⁽²⁾	08/12/2023	Common Stock	22,374	$3.45	D

Explanation of Responses:

1. The options of registrant's common stock vested as to 25% of the shares on the one-year anniversary of the grant and in equal monthly installments over the next three years thereafter.

2. The options of registrant's common stock vest in equal monthly installments over the first four years after the grant.

3. The options of registrant's common stock vested as to 100% of the shares on the date of the grant.

4. The options of registrant's common stock vested based on the registrant's satisfaction of certain milestone performance criteria.

Remarks:

Exhibit ListExhibit 24 - Power of Attorney

	/s/ Robert E. Farrell, Jr., as attorney-in-fact for George Siber	02/04/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.